Home › Research › Health systems and care delivery
Long-term value of lecanemab to individuals and families
Tysinger Bryan, Wei Yifan, Heun-Johnson Hanke, Zissimopoulos Julie M. Alzheimer's & dementia (New York, N. Y.), 2025-09-02
Topic: Risk, prevention and care in population studies
Plain-language summary
An assessment of the value of lecanemab for patients living with Alzheimer's disease (AD) and their care partners provides them and their health-care providers important information for deciding treatment initiation. We used data from a nationally representative sample of middle aged and older Americans combined with data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) on AD progression and data on lecanemab treatment effects from Clarity AD clinical trials. We use dynamic microsimulation modeling to quantify the long-term health and economic value of lecanemab for persons living with AD and their care partners. We quantified five measures of value: quality of life of the persons living with AD and their care partners, medical costs, caregiving costs, and earnings, and estimated that lecanemab had a value of $21,398 relative to no treatment after 4 years and $37,943 after 10 years. Extending the treatment to 48 months resulted in a value of $42,821 relative to no treatment after 4 years and $95,311 after 10 years. Forty-eight months of a similar next-generation therapy but with 50% efficacy in slowing cognitive and functional decline resulted in a value of $82,116 relative to no treatment after 4 years and $189,691 after 10 years. Over time, lecanemab treatment reduced medical costs, hours of care required from care partners, and improved quality of life. There is much value to be gained with next-generation treatments that have a larger impact on slowing decline. Considering a wider range of outcomes in future assessments will provide a more complete understanding of value to support decision making about treatment initiation and about reimbursement for payers. There is significant value of lecanemab for persons with mild cognitive impairment or mild dementia.Over time, lecanemab reduces medical costs, caregiver hours, and improves the quality of life of persons living with Alzheimer's disease (AD) and their care partners.A next-generation treatment for AD with similar features to lecanemab but higher efficacy, more than doubles the value.Assessing therapy value supports decision making by patients and their health-care providers.
What this study adds
Evidence grade: Low
This modeling study estimated the long-term health and economic value of lecanemab for people with Alzheimer's disease and their care partners, finding reduced medical costs, fewer caregiving hours, and improved quality of life over time. It is a simulation based on trial and cohort data, not a new clinical trial of cure or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Bryan, T., Yifan, W., Hanke, H.-J., & Zissimopoulos Julie, M. (2025). Long-term value of lecanemab to individuals and families. Alzheimer's & dementia (New York, N. Y.). https://doi.org/10.1002/trc2.70151
Vancouver
Bryan T, Yifan W, Hanke H.-J, Zissimopoulos Julie M. Long-term value of lecanemab to individuals and families. Alzheimer's & dementia (New York, N. Y.). 2025. doi:10.1002/trc2.70151. PMID: 40895811.
BibTeX
@article{bryan2025-40895811,
author = {Bryan, Tysinger and Yifan, Wei and Hanke, Heun-Johnson and Zissimopoulos Julie, M.},
title = {{Long-term value of lecanemab to individuals and families}},
journal = {Alzheimer's \& dementia (New York, N. Y.)},
year = {2025},
doi = {10.1002/trc2.70151},
pmid = {40895811},
url = {https://doi.org/10.1002/trc2.70151}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- There is significant value of lecanemab for persons with mild cognitive impairment or mild dementia.Over time, lecanemab reduces medical costs, caregiver hours, and improves the quality of life of persons living with Alzheimer's disease (AD) and their care partners.A next-generation treatment for AD with similar features to lecanemab but higher efficacy, more than doubles the value.Assessing therapy value supports decision making by patients and their health-care providers.
Why it matters
This modeling study estimated the long-term health and economic value of lecanemab for people with Alzheimer's disease and their care partners, finding reduced medical costs, fewer caregiving hours, and improved quality of life over time. It is a simulation based on trial and cohort data, not a new clinical trial of cure or prevention.
Study details
- Evidence strengthLow
How this study scored 41/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia (New York, N. Y.)) |
| Journal's citation record | 1 / 4 | Alzheimer s & Dementia Translational Research & Clinical Interventions: journal h-index 84 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 8 times (OpenAlex, 2026-10-17) |
| Citations per year | 1 / 5 | 2.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 4.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 6 other studies in this library |
| Still being cited | 1 / 4 | Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Julie Zissimopoulos: h-index 36 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Southern California: institution h-index 1,524 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40895811) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
6 studies in the alzhub library list this one in their references.
Related studies in Health systems and care delivery from nearby years
Also in Health systems and care delivery
172 studies in the library are filed under Health systems and care delivery with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Health systems and care delivery hub.